Scientists have reported progress in a technique to stimulate the lower spinal cord in paraplegics to help them recover lost nerve function.

Cautiously tested on a single patient three years ago, the technique has been trialled on three other young men who had been paraplegic for at least two years after road accidents, they said on Tuesday.

After the patients were given an implant to stimulate nerve bundles in the lower spine, they were able to voluntarily flex their knees and shift their hips, ankles and toes, the team reported in a published study.

The four were not able to walk but could bear some weight independently - a key phase towards this goal - and experienced a 'dramatic' improvement in wellbeing, they added.

Claudia Angeli of the University of Louisville's Kentucky Spinal Cord Injury Research Center (KSCIRC) said two of the men had been diagnosed not only as paralysed in the legs, but also lacking lower-body sensation, with no chance of recovery.

'This is groundbreaking for the entire field and offers a new outlook that the spinal cord, even after a severe injury, has great potential for functional recovery,' Angeli said in a statement.

Paralysis comes from damage to the spinal cord down which the brain sends electrical signals along nerve fibres to instruct limb movement.

Decades of experimental effort have been devoted to reconnecting severed fibres through surgery or regrowing them through drugs or stem cells.

The new research takes a different route, exploring the idea that there are ways paralysed people can move without reconnecting the nerve link between the brain and lower extremities.

It delivers tiny electrical signals to networks in the lumbosacral spinal cord that are relatively autonomous - they can follow through the commands for weight-bearing and coordinated stepping without input from the brain.

See the article here:
Progress in electrical nerve treatment

'This is groundbreaking for the entire field and offers a new outlook that the spinal cord, even after a severe injury, has great potential for functional recovery'

PARIS, France Scientists on Tuesday, April 8 reported progress in a technique to stimulate the lower spinal cord in paraplegics to help them recover lost nerve function.

Cautiously tested on a single patient 3 years ago, the technique has been trialed on 3 other young men who had been paraplegic for at least two years after road accidents, they said.

After the patients were given an implant to stimulate nerve bundles in the lower spine, they were able to voluntarily flex their knees and shift their hips, ankles and toes, the team reported in a published study.

The 4 were not able to walk but could bear some weight independently -- a key phase towards this goal -- and experienced a "dramatic" improvement in wellbeing, they added.

Claudia Angeli of the University of Louisville's Kentucky Spinal Cord Injury Research Center (KSCIRC) said two of the men had been diagnosed not only as paralysed in the legs, but also lacking lower-body sensation, with no chance of recovery.

"This is groundbreaking for the entire field and offers a new outlook that the spinal cord, even after a severe injury, has great potential for functional recovery," Angeli said in a press release.

Paralysis comes from damage to the spinal cord down which the brain sends electrical signals along nerve fibers to instruct limb movement.

Decades of experimental effort have been devoted to reconnecting severed fibers through surgery or regrowing them through drugs or stem cells.

Read the original:
Scientists make progress in treating paralysis

Brenda Goodman HealthDay Reporter Posted: Monday, April 7, 2014, 4:00 PM

MONDAY, April 7, 2014 (HealthDay News) -- In an early test, researchers report they've safely injected stem cells into the brains of 18 patients who had suffered strokes. And two of the patients showed significant improvement.

All the patients saw some improvement in weakness or paralysis within six months of their procedures. Although three people developed complications related to the surgery, they all recovered. There were no adverse reactions to the transplanted stem cells themselves, the study authors said.

What's more, the researchers said, two patients experienced dramatic recoveries almost immediately after the treatments.

Those patients, who were both women, started to regain the ability to talk and walk the morning after their operations. In both cases, they were more than two years past their strokes, a point where doctors wouldn't have expected further recovery.

The results have encouraged researchers to plan larger and longer tests of the procedure, which uses stem cells cultured from donated bone marrow.

An expert who was not involved in the research called it a promising first step.

"It's a small, early human study. It takes multiple steps to get to something clinically useful, and this is a nice, early step," said Dr. Steven Cramer, clinical director of the Stem Cell Research Center at the University of California, Irvine.

The findings were to be presented Monday at the American Association of Neurological Surgeons annual meeting, in San Francisco. The results of studies presented at meetings are considered preliminary until they've been published in peer-reviewed medical journals.

Visit link:
Stem Cells Show Promise for Stroke Recovery

PUBLIC RELEASE DATE:

8-Apr-2014

Contact: Vanessa Wasta wasta@jhmi.edu 410-614-2916 Johns Hopkins Medicine

Research in mice and human cell lines has identified an experimental compound dubbed TTT-3002 as potentially one of the most potent drugs available to block genetic mutations in cancer cells blamed for some forms of treatment-resistant leukemia.

Results of the research by Johns Hopkins Kimmel Cancer Center investigators, described March 6 in the journal Blood, show that two doses a day of TTT-3002 eliminated leukemia cells in a group of mice within 10 days. The treatment performed as well as or better than similar drugs in head-to-head comparisons.

More than 35 percent of acute myeloid leukemia (AML) patients harbor a mutation in the gene FMS-like tyrosine kinase-3 (FLT3). Normal FLT3 genes produce an enzyme that signals bone marrow stem cells to divide and replenish. But when FLT3 is mutated in some AML patients, the enzyme stays on permanently, causing rapid growth of leukemia cells and making the condition likely to relapse after treatment.

Many investigators are developing and testing drugs designed to block the FLT3 enzyme's proliferation, several of which are now in clinical trials. So far, their effectiveness has been limited, according to Donald Small, M.D., Ph.D., the Kyle Haydock Professor of Oncology and director of pediatric oncology at Johns Hopkins. Small led a team of researchers who originally cloned the FLT3 gene and linked it to leukemia a decade ago.

"We're very excited about TTT-3002, because it appears in our tests so far to be the most potent FLT3 inhibitor to date," says Small. "It showed activity against FLT3-mutated cells taken from patients and with minimal toxicity to normal bone marrow cells, making it a promising new candidate for the treatment of AML."

In a series of experiments with the drug, Small, postdoctoral fellow Hayley Ma, Ph.D., and others found that the amount of TTT-3002 needed to block FLT3 activity in human leukemia cell lines was six- to sevenfold lower than for the most potent inhibitor currently in clinical trials. TTT-3002 also inhibited proteins made by genes further down the FLT3 signaling pathway, including STAT5, AKT and MAPK, and showed activity against the most frequently occurring FLT3 mutations, FLT3/ITD and FLT3/D835Y. Many cancer drugs are currently ineffective against FLT3/D835Y mutations.

When the Johns Hopkins team tested the drug in a mouse model of leukemia, they found that it not only eliminated the presence of leukemic cells within 10 days of treatment but also that the mice lived an average of more than 100 days following treatment, to study completion, and resumed normal bone marrow activity. By contrast, mice treated with a placebo died an average of 18 days following treatment.

See the original post here:
Experimental drug shows promise for treatment-resistant leukemias

LONDON In a north London hospital, scientists are growing noses, ears and blood vessels in the laboratory in a bold attempt to make body parts using stem cells.

It is among several labs around the world, including in the US, that are working on the futuristic idea of growing custom-made organs in the lab.

While only a handful of patients have received the British lab-made organs so far including tear ducts, blood vessels and windpipes researchers hope they will soon be able to transplant more types of body parts into patients, including what would be the worlds first nose made partly from stem cells.

Its like making a cake, said Alexander Seifalian at University College London, the scientist leading the effort. We just use a different kind of oven.

Dr. Michelle Griffin, a plastic surgery research fellow, holds a synthetic polymer ear.Photo: AP

During a recent visit to his lab, Seifalian showed off a sophisticated machine used to make molds from a polymer material for various organs.

Last year, he and his team made a nose for a British man who lost his to cancer. Scientists added a salt and sugar solution to the mold of the nose to mimic the somewhat sponge-like texture of the real thing. Stem cells were taken from the patients fat and grown in the lab for two weeks before being used to cover the nose scaffold. Later, the nose was implanted into the mans forearm so that skin would grow to cover it.

Seifalian said he and his team are waiting for approval from regulatory authorities to transfer the nose onto the patients face but couldnt say when that might happen.

The potential applications of lab-made organs appear so promising, even the city of London is getting involved: Seifalians work is being showcased on Tuesday as Mayor Boris Johnson announces a new initiative to attract investment to Britains health and science sectors so spin-off companies can spur commercial development of the pioneering research.

The polymer material Seifalian uses for his organ scaffolds has been patented and hes also applied for patents for their blood vessels, tear ducts and windpipe. He and his team are creating other organs including coronary arteries and ears. Later this year, a trial is scheduled to start in India and London to test lab-made ears for people born without them.

Original post:
Sci-fi meets reality as stem cells are turned into noses, ears

Professor Alexander Seifalian poses for photographs with a synthetic polymer nose at his research facility in the Royal Free Hospital in London, Monday, March 31, 2014. In a north London hospital, scientists are growing noses, ears and blood vessels in the laboratory in a bold attempt to make body parts using stem cells. AP

In a north London hospital, scientists are growing noses, ears and blood vessels in the laboratory in a bold attempt to make body parts using stem cells.

It is among several labs around the world, including in the U.S., that are working on the futuristic idea of growing custom-made organs in the lab.

5 Photos

In a north London hospital, scientists are growing noses, ears and blood vessels in attempt to make body parts using stem cells

"It's like making a cake," said Alexander Seifalian at University College London, the scientist leading the effort. "We just use a different kind of oven."

During a recent visit to his lab, Seifalian showed off a sophisticated machine used to make molds from a polymer material for various organs.

Last year, he and his team made a nose for a British man who lost his to cancer. Scientists added a salt and sugar solution to the mold of the nose to mimic the somewhat sponge-like texture of the real thing. Stem cells were taken from the patient's fat and grown in the lab for two weeks before being used to cover the nose scaffold. Later, the nose was implanted into the man's forearm so that skin would grow to cover it.

Seifalian said he and his team are waiting for approval from regulatory authorities to transfer the nose onto the patient's face but couldn't say when that might happen

The potential applications of lab-made organs appear so promising even the city of London is getting involved: Seifalian's work is being showcased on Tuesday as Mayor Boris Johnson announces a new initiative to attract investment to Britain's health and science sectors so spin-off companies can spur commercial development of the pioneering research.

View post:
Ears, noses grown from stem cells in lab dishes

London's Royal Free hospital is among several in the world that are working on the futuristic idea of growing custom-made organs in the lab Few have received the lab-made organs so far - including ears and windpipes - but researchers hope they will soon transplant more They hope to transplant world's first nose made partly from stem cells

By Associated Press and Ellie Zolfagharifard

Published: 05:38 EST, 8 April 2014 | Updated: 12:09 EST, 8 April 2014

664 shares

56

View comments

At London's Royal Free hospital, scientists are growing noses, ears and blood vessels in the laboratory in a bold attempt to make body parts using stem cells.

It is among several labs around the world, including in the U.S., that are working on the futuristic idea of growing custom-made organs in the lab.

Only a handful of patients have received the British lab-made organs so far - including tear ducts, blood vessels and windpipes.

But researchers hope they will soon be able to transplant more types of body parts into patients, including what would be the world's first nose made partly from stem cells.

Excerpt from:
British scientists make custom-made body parts using stem cells

Bradley J. Fikes

Stem-cell biologist Mahendra Rao expected five projects to receive support to set up clinical trials.

Stem-cell researchers at the US National Institutes of Health (NIH) have been left frustrated and confused following the demise of the agencys Center for Regenerative Medicine (CRM). The intramural programmes director, stem-cell biologist Mahendra Rao, left the NIH, in Bethesda, Maryland, on 28March, and the centres website was taken down on 4 April. Although no official announcement had been made at the time Nature went to press, NIH officials say that they are rethinking how they will conduct in-house stem-cell research.

Researchers affiliated with the centre say that they have been left in the dark. When contacted by Nature on 7April, George Daley, a stem-cell biologist at Harvard Medical School in Boston, Massachusetts, and a member of the centres external advisory board, said that he had not yet been told of Raos departure or the centres closure.

The CRM was established in 2010 to centralize the NIHs stem-cell programme. Its goal was to develop useful therapies from induced pluripotent stem (iPS) cells adult cells that have been converted into embryonic-like stem cells and shepherd them towards clinical trials and regulatory approval. Its budget was intended to be $52million over seven years.

Rao took the helm in 2011. Relations seem to have soured last month owing to an NIH decision to award funding to only one project aiming to move iPS cells into a clinical trial. Rao says he resigned after this became clear. He says that he had hoped that five trials would be funded, especially because the centre had already sorted out complex issues relating to tissue sources, patents and informed consent.

James Anderson, director of the NIHs Division of Program Coordination, Planning, and Strategic Initiatives, which administered the CRM, counters that only one application that made by Kapil Bharti of the National Eye Institute in Bethesda and his colleagues received a high enough score from an external review board to justify continued funding. The team aims to use iPS cells to treat age-related macular degeneration of the retina, and hopes to commence human trials within a few years. Several other proposals, which involved the treatment of cardiac disease, cancer and Parkinsons disease, will not receive funding to ready them for clinical trials. Anderson stresses that Bhartis trial will not be affected by the CRMs closure.

NIH

Therapies based on induced pluripotent stem cells, here differentiating into retinal cells on a scaffold, were the focus of the Center for Regenerative Medicine.

Other human iPS-cell trials are further along. For example, one on macular degeneration designed by Masayo Takahashi at the RIKEN Center for Developmental Biology in Kobe, Japan, began recruiting patients last August.

Link:
NIH stem-cell programme closes

The director of the agency's Center for Regenerative Medicine resigned on March 28 after just one clinical-trial award had been made

Therapies based on induced pluripotent stem cells, here differentiating into retinal cells on a scaffold, were the focus of the Center for Regenerative Medicine. Credit: NIH

Stem-cell researchers at the National Institutes of Health (NIH) have been left frustrated and confused following the demise of the agencys Center for Regenerative Medicine (CRM). The intramural programs director, stem-cell biologist Mahendra Rao, left the NIH, in Bethesda, Maryland, on 28March, and the centers website was taken down on 4 April. Although no official announcement had been made at the timeNaturewent to press, NIH officials say that they are rethinking how they will conduct in-house stem-cell research.

Researchers affiliated with the center say that they have been left in the dark. When contacted byNatureon 7April, George Daley, a stem-cell biologist at Harvard Medical School in Boston, Massachusetts, and a member of the centers external advisory board, said that he had not yet been told of Raos departure or the centers closure.

The CRM was established in 2010 to centralize the NIHs stem-cell program. Its goal was to develop useful therapies from induced pluripotent stem (iPS) cells adult cells that have been converted into embryonic-like stem cells and shepherd them towards clinical trials and regulatory approval. Its budget was intended to be $52million over seven years.

Rao took the helm in 2011. Relations seem to have soured last month owing to an NIH decision to award funding to only one project aiming to move iPS cells into a clinical trial. Rao says he resigned after this became clear. He says that he had hoped that five trials would be funded, especially because the center had already sorted out complex issues relating to tissue sources, patents and informed consent.

James Anderson, director of the NIHs Division of Program Coordination, Planning, and Strategic Initiatives, which administered the CRM, counters that only one application that made by Kapil Bharti of the National Eye Institute in Bethesda and his colleagues received a high enough score from an external review board to justify continued funding. The team aims to use iPS cells to treat age-related macular degeneration of the retina, and hopes to commence human trials within a few years. Several other proposals, which involved the treatment of cardiac disease, cancer and Parkinsons disease, will not receive funding to ready them for clinical trials. Anderson stresses that Bhartis trial will not be affected by the CRMs closure.

Other human iPS-cell trials are further along. For example, one on macular degeneration designed by Masayo Takahashi at the RIKEN Center for Developmental Biology in Kobe, Japan, began recruiting patients last August.

Anderson says that the CRM will not continue in its current form. The field is moving so fast that we need to rethink. To that end, the NIH plans to hold a workshop in May to gather stem-cell researchers together and decide what to do with the program and its remaining budget. To me thats just smart science, he says. If somethings not on track you dont keep spending money on it.

One option could be to allow CRM projects to be absorbed by the National Center for Advancing Translational Sciences, an NIH institute established in 2011 to translate basic research into therapies. But Anderson says that participants at the workshop will also discuss whether the NIH needs to replace the CRM with another dedicated stem-cell program.

Continued here:
NIH Stem-Cell Program Closes

Emcell Autism Arabic

By: Stem Cell Therapy Center EMCELL

Read more:
Emcell Autism Arabic - Video

Stem Cell Therapy for Chronic Pain

By: Latest Pain Relief Solutions

See more here:
Stem Cell Therapy for Chronic Pain - Video

News 12: Stem Cell Therapy for Pain

By: Latest Pain Relief Solutions

Continued here:
News 12: Stem Cell Therapy for Pain - Video

A doctor offering stem cell therapy may face charges for the death of a cancer patient who allegedly underwent treatment similar to that administered to former president and incumbent Pampanga Rep. Gloria Macapagal-Arroyo.

This was after it was found out that she is not a licensed doctor in the Philippines.

A report on GMA News TV's "News To Go" on Wednesday said a complaint has been filed against Dr. Antonia Carandang-Park at the National Bureau of Investigation (NBI) by Bernard Tan, who claims that his daughter, Kate, died after going through the said alternative treatment.Cancer patient Kate Tan received stem cell therapy from Dr. Antonia Carandang-Park, Gloria Arroyo's doctor.

Park owns the Tagaytay-based Green & Young Health and Wellness Center where Arroyoburdened by persistent trouble with her cervical spinesought treatment in 2012.

In an interview with GMA News, Tan said his daughter, who had Hodgkin's lymphoma (a type of cancer of the blood), was given "the same treatment that [Park] did with Gloria," which included "juicing diet, vegetable diet... acupuncture coffee enema, at 'yun na nga, stem cell."

Stem cell therapy introduces new adult stem cells into damaged tissue in order to treat disease or injury.

"Ang sabi niya, 'Give me three months, magaling na 'yan,'" Tan told GMA News. He added that his family was easily convinced to take their daughter to Park's wellness center because "Presidente na ng Pilipinas ang pumunta doon."

"Siguro naman na-scrutinize na nila 'yan, na-background check na nila 'yan," he said. "Kumbaga, 'yung credibility no'n, nag-build up na."

Kate was fed nothing but bananas and vegetable juices for three months, and had eight rounds of "embryonic" stem cell treatment, he said.

However, the 23-year-old lost even more weight, prompting the family to seek the assistance of a different doctor. Kate had eight rounds of 'embryonic' stem cell treatment, her father Bernard Tan said.Seven months later, in July 2013, Kate passed away.

Read the rest here:
Gloria Arroyos stem cell therapy doc blamed for cancer patient's death

New York, NY (PRWEB) April 09, 2014

The Stem Cell Institute, located in Panama City, Panama, will present an informational umbilical cord stem cell therapy seminar on Saturday, May 17, 2014 in New York City at the New York Hilton Midtown from 1:00 pm to 4:00 pm.

Speakers include:

Neil Riordan PhD Clinical Trials: Umbilical Cord Mesenchymal Stem Cell Therapy for Autism and Spinal Cord Injury

Dr. Riordan is the founder of the Stem Cell Institute and Medistem Panama Inc.

Jorge Paz-Rodriguez MD Stem Cell Therapy for Autoimmune Disease: MS, Rheumatoid Arthritis and Lupus

Dr. Paz is the Medical Director at the Stem Cell Institute. He practiced internal medicine in the United States for over a decade before joining the Stem Cell Institute in Panama.

Light snacks will be served afterwards. Our speakers and stem cell therapy patients will also be on hand to share their personal experiences and answer questions.

Admission is free but space in limited and registration is required. For venue information and to register and reserve your tickets today, please visit: http://www.eventbrite.com/e/stem-cell-institute-seminar-tickets-11115112601 or call Cindy Cunningham, Patient Events Coordinator, at 1 (800) 980-7836.

About Stem Cell Institute Panama

The rest is here:
Stem Cell Institute Public Seminar on Adult Stem Cell Therapy Clinical Trials in New York City May 17th, 2014

Kent Stephenson lies down during voluntary training while Katelyn Gurley (not seen) tracks his level of muscle activity and force at the Human Locomotion Research Center laboratory, Frazier Rehab Institute, as part of the University of Louisvilles Kentucky Spinal Cord Injury Research Center in Louisville, Kentucky. Photograph: University of Louisville/Handout via Reuters

Four men who had each been paralysed from the chest down for more than two years and had been told their situation was hopeless regained the ability to voluntarily move their legs and feet - though not to walk - after an electrical device was implanted in their spines, researchers reported today.

The success, albeit in a small number of patients, offers hope that a fundamentally new treatment can help many of the millions of paralysed people.Even those whose cases are deemed so hopeless they are not offered further rehabilitation might benefit, scientists say.

The results also cast doubt on a key assumption about spinal cord injury: that treatment requires damaged neurons to regrow or be replaced with, for instance, stem cells. Both approaches have proved fiendishly difficult and, in the case of stem cells, controversial.

The big message here is that people with spinal cord injury of the type these men had no longer need to think they have a lifelong sentence of paralysis, Dr Roderic Pettigrew, director of the National Institute of Biomedical Imaging and Bioengineering, part of the National Institutes of Health, said in an interview.

They can achieve some level of voluntary function, which he called a milestone in spinal cord injury research. His institute partly funded the study, which was published in the journal Brain.

The partial recovery achieved by hopeless patients suggests that physicians and rehabilitation therapists may be giving up on millions of paralysed people. Thats because physical therapy can mimic some aspects of the electrical stimulation that the device provided, said Susan Harkema, a specialist in neurological rehab at the University of Louisvilles Kentucky Spinal Cord Injury Research Center (KSCIRC), who led the new study.

One of the things this research shows is that there is more potential for spinal cord injury patients to recover even without this electrical stimulation, she said in an interview. Today, patients are not given rehab because they are not considered good investments. We should rethink what theyre offered, because rehabilitation can drive recovery for many more than are receiving it.

The research built on the case of a single paralysed patient that Ms Harkemas team reported in 2011. College baseball star Rob Summers had been injured in a hit-and-run accident in 2006, paralysing him below the neck.

In late 2009, Summers received the epidural implant just below the damaged area. The 72-gramme device began emitting electrical current at varying frequencies and intensities, stimulating dense bundles of neurons in the spinal cord. Three days later he stood on his own. In 2010 he took his first tentative steps.

See the original post:
Paralysed men regain movement after spinal implant, study finds

A Calgary blood and marrow transplant doctor says hes looking forward to the establishment of a national cord blood bank, which will provide stem cells for procedures at two city hospitals once its fully up and running later this year.

The National Cord Blood Bank, run by Canadian Blood Services, is set to become the first public cord blood bank in the country, with hospitals in Edmonton, Ottawa, Vancouver and Brampton designated as collection sites.

Dr. Victor Lewis, a pediatric oncologist at the Alberta Childrens Hospital, said the stem cells collected from cord blood can make a huge difference for patients by increasing the inventory doctors can search to find donors.

Theres a good chance we may find donors for Canadian children in the Canadian cord bank, he said, noting cord blood stem cells are biologically younger and considered more flexible for treatment options compared to adult cells.

Umbilical cord blood is a sought-after source for stem cells since the match doesnt have to be as precise for the young cells, compared with bone marrow sources, said Heidi Elmaoazzen, director of the national public cord blood bank.

Until the first phase of the project opened in Ottawa last year, umbilical cords were considered medical waste, said Elmaoazzen, speaking to a Calgary Herald editorial board meeting.

The national centre will now cryopreserve the material collected from the four donor hospitals and store it indefinitely for use treating diseases such as leukemia and lymphoma.

In Calgary, it will allow physicians to perform stem cell transplants at the Alberta Childrens Hospital and Tom Baker Cancer Centre.

The agency has raised about $7.8 million of its $12.5-million fundraising goal for the project, said campaign co-chair Dale Sheard.

The rest of the funds for the $48-million blood bank are set to come from provincial and territorial governments, apart from Quebec.

Read the original post:
Calgary childrens hospital eager for access to national cord blood bank

(PRWEB) April 08, 2014

CELL SURGICAL NETWORK

Originating in California, CSN is the worlds largest cell surgical network and first multidisciplinary Regenerative Medicine group. CSN is collaborating with the Australian Adult Stem Cell Foundation to bring the research network to Australia.

CSN HAS OVER 40 LOCATIONS within the United States and several more worldwide. CSN has recently been launched in Australia with hand selected approved board certified Physicians. The ASCF has played an important role to identifying physicians who are passionate about regenerative and integrated medicine with a strong interest in SVF cell transplants.

INTERNATIONAL PHYSICIAN GROUP- Physicians belonging to the CSN network join an international network of Board certified Physicians, creating a multidisciplinary team where they receive training, technology and IP transfer, education and support for physicians and staff, access to IRB approved research protocols, the opportunity to submit their own protocols for IRB approval, website presence, and access to a university quality research database that collects outcomes from all sites.

SVF PROCUREMENT- The CSN SVF isolation system is a completely closed sterile surgical procedure. There are no laboratory requirements (e.g. laminar flow hood or otherwise) avoiding issues of GMP maintenance or possible cross contamination from laboratory handling. Further, the unique double filtration system avoids any risks of Pulmonary Emboli (PE) or problems due to particulate matter. The CSN has over the last 4 years researched and designed equipment that supports new requirements supported by the FDA/TGA. As the CSN system is a closed sterile surgical system it can be done in a doctors office and adheres to FDA/TGA regulations.

IRB STUDIES- Areas of study by the Cell Surgical Network include Orthopedics, Urology, Neurology, Cardiac/Pulmonary, Auto-Immune Diseases, Lichen Sclerosis, Ophthalmology. See http://www.stemcellrevolution.com

JOINING CELL SURGICAL NETWORK - Physicians interested in participating in the Cell Surgical Network please contact Chris Lindholm for more information by emailing clindholm(at)cellsurgicalnetwork(dot)com or phone 800-231-0407.

Read this article:
Cell Surgical Network Opening in Australia

Stem Cells for back pain, Dr. Grande
Stem cell Therapy for spine disease explained.

By: SunCoastSeminars

Read more here:
Stem Cells for back pain, Dr. Grande - Video

Desiccated L4/5 disc five months after stem cell therapy by Dr Harry Adelson
A decorated war hero, Chris, discusses the stem cell injection into his L4/5 disc by Dr Harry Adelson http://www.docereclinics.com.

By: Harry Adelson, N.D.

See more here:
Desiccated L4/5 disc five months after stem cell therapy by Dr Harry Adelson - Video

Stem Cell Therapy for Dogs and Cats
Stem Cells are extracted from your pet #39;s fatty tissue, and processed with Platelet Rich Plasma (PRP) into an injectable solution, which is then activated usi...

By: Vet4bulldog

Go here to read the rest:
Stem Cell Therapy for Dogs and Cats - Video